Skip to main content

Advertisement

Table 3 Sensitivity analysis: incremental cost-effectiveness ratio (ICER) of HPV vaccination* in Estonia, model estimates.

From: The epidemiological and economic impact of a quadrivalent human papillomavirus (hpv) vaccine in Estonia

  ICER € per QALYs
Base case 4889
Screening characteristics  
Under hypothetical improved cervical screening program** 6167
Vaccine characteristics  
Assuming no HPV 6/11 protection 5771
Duration of protection = 20 years 8090
Vaccination characteristics  
Low vaccine coverage (70%) 4444
High vaccine coverage (95%) 5212
Costs characteristics  
Cost of diagnosis and treatment +20% 4744
Cost of diagnosis and treatment −20% 5037
Cost of vaccine - 10% 4351
Cost of vaccine + 10% 5454
Health utility values  
Cost per life year saved (no quality of life adjustments) 6746
Discount rate  
Discount rate 0% 1517
Discount rate 5% 11148
  1. * HPV6/11/16/18 related cervical cancer and genital warts.
  2. **Vaccination program introduced alongside hypothetical improved cervical screening program.